- Combination of a beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity
-
We report the novel combination of a selective beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor (sibutramine) with potential for the treatment of obesity. The synthesis and characterization of 6-[4-[2-[[(2S)-3-(9H-carbazol-4-ylo
- Jesudason, Cynthia D.,Baker, James E.,Bryant, Robert D.,Fisher, Jack W.,O'Farrell, Libbey S.,Gaich, Gregory A.,He, Minxia M.,Kahl, Steven D.,Kriauciunas, Aidas V.,Heiman, Mark L.,Peters, Mary A.,Rito, Christopher J.,Satterwhite, Julie H.,Tinsley, Frank C.,Trankle, William G.,Shuker, Anthony J.
-
-
Read Online
- SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST
-
The present invention provides a compound of formula (I) in acetate salt form (I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents a
- -
-
Page/Page column 36-37
(2014/03/25)
-
- BENZOTHIAZOLONE COMPOUND
-
The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination o
- -
-
Paragraph 38; 39
(2013/03/26)
-
- BENZOTHIAZOLONE COMPOUND
-
The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of p
- -
-
Paragraph 0217-0219
(2013/09/26)
-
- (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES
-
Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula 1, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases
- -
-
Page/Page column 76
(2012/10/08)
-
- Methods and compositions for treating amyloid-related diseases
-
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
- -
-
Page/Page column 152
(2010/11/24)
-
- Potent benzimidazolone based human β3-adrenergic receptor agonists
-
The synthesis and biological evaluation of a series of benzimidazolone β3 adrenergic receptor agonists are described. A trend toward the reduction of rat atrial tachycardia upon increasing steric bulk at the 3-position of the benzimidazolone mo
- Finley, Don R.,Bell, Michael G.,Borel, Anthony G.,Bloomquist, William E.,Cohen, Marlene L.,Heiman, Mark. L.,Kriauciunas, Aidas,Matthews, Donald P.,Miles, Tania,Neel, David A.,Rito, Christopher J.,Sall, Daniel J.,Shuker, Anthony J.,Stephens, Thomas W.,Tinsley, Frank C.,Winter, Mark A.,Jesudason, Cynthia D.
-
p. 5691 - 5694
(2007/10/03)
-
- Aryloxy propanolamines for improving livestock production
-
Disclosed is a compound represented by structural formula (I): R1 is a substituted or unsubstituted aryl group. R2 and R3 are independently —H, a C1-C4 straight chained or branched alkyl group. R4 and R5 are independently —H, a C1-C4 straight chained or b
- -
-
Page column 11
(2010/02/10)
-
- Indazolyloxy propanolamines for improving livestock production
-
Disclosed is compound represented by Structural Formula (I), wherein Ring A, Ring B and Ring C are independently substituted or unsubstituted. R1 and R2 are independently a C1-C4 straight chained or branched alkyl group. Also disclosed is a method of incr
- -
-
-
- Carbazolyl-substituted ethanolamines as selective beta -3 agonists
-
PCT No. PCT/US97/15230 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Aug. 28, 1997 PCT Pub. No. WO98/09625 PCT Pub. Date Mar. 12, 1998Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
- -
-
-
- SELECTIVE BETA3 ADRENERGIC AGONISTS
-
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I:
- -
-
-
- SELECTIVE BETA 3 ADRENERGIC AGONISTS
-
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: STR1
- -
-
-
- Selective beta3 adrenergic agonists
-
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and
- -
-
-